Gevraagd door: Karolina Trikkis
VRAAGSTELLER Algemeen

Signatera Oncology Portal

Link van Signatera Oncology Portal pagina wordt hieronder gegeven. Pagina's met betrekking tot Signatera Oncology Portal worden ook vermeld.

Laatst bijgewerkt: 2022-02-06 23:48:14

7

Toegevoegd door: James Gillies

Uitlegger

Signatera FAQ | Natera

Signatera is not a traditional oncology test. It does not focus on well-characterized mutations, oncogenes or hotspots like most tests. Instead, Signatera utilizes a WES-based, tumor-informed approach to create 16 bespoke assays that target specific, and generally unique, mutations found in your patient’s tumor, but absent in their germline DNA.
Url: https://www.natera.com/oncology/signatera-advanced-cancer-detection/faq/
Signatera FAQ | Natera

UNKNOWN

Maandelijkse bezoeken

0

Alexa Rank

UNKNOWN

Populair in

Up

Service status

Toegevoegd door: Ivan Holloway

Uitlegger

Signatera for Patients | Natera

Signatera is a blood MRD test used for cancer detection and surveillance. It is personalized for each patient. It is used for molecular residual disease assessment and for treatment response monitoring. A doctor may order Signatera along with routine follow-up exams to …
Url: https://www.natera.com/oncology/signatera-advanced-cancer-detection/patients/
Signatera for Patients | Natera

UNKNOWN

Maandelijkse bezoeken

0

Alexa Rank

UNKNOWN

Populair in

Up

Service status

Toegevoegd door: Gary Skewes

Uitlegger

Study Shows Natera's Signatera MRD Test Predictive Of ...

Jan 23, 2022 · (RTTNews) - The Landmark CIRCULATE-Japan Study Showed Natera Inc.'s (NTRA) Signatera MRD Test is predictive of chemotherapy benefit in Colorectal Cancer. More than 3,000 cohort of colorectal ...
Url: https://www.nasdaq.com/articles/study-shows-nateras-signatera-mrd-test-predictive-of-chemotherapy-benefit-in-colorectal
Study Shows Natera's Signatera MRD Test Predictive Of ...

60,833,747

Maandelijkse bezoeken

1,626

Alexa Rank

US

Populair in

Up

Service status

Toegevoegd door: Sally London

Uitlegger

JP Morgan Healthcare Conference Day 1: Novartis, Gilead ...

Jan 11, 2022 · This article has been corrected to reflect that EQRx went public via a $1.3 billion special purpose acquisition company deal. NEW YORK – The 40th Annual JP Morgan Healthcare Conference kicked off on Monday, as conference organizers pivoted to a virtual conference instead of the usual live event at the Westin St. Francis Hotel in San Francisco due to the …
Url: https://www.precisiononcologynews.com/cancer/jp-morgan-healthcare-conference-day-1-novartis-gilead-johnson-johnson-eqrx-mirati-and-more
JP Morgan Healthcare Conference Day 1: Novartis, Gilead ...

UNKNOWN

Maandelijkse bezoeken

0

Alexa Rank

UNKNOWN

Populair in

Up

Service status

Toegevoegd door: Simon Kaddatz

Uitlegger

Cancers | Free Full-Text | Optimizing the Diagnosis and ...

Jan 13, 2022 · Cholangiocarcinoma (CCA) is a heterogenous group of malignancies originating in the biliary tree, and associated with poor prognosis. Until recently, treatment options have been limited to surgical resection, liver-directed therapies, and chemotherapy. Identification of actionable genomic alterations with biomarker testing has revolutionized the treatment …
Url: https://www.mdpi.com/2072-6694/14/2/392/htm
Cancers | Free Full-Text | Optimizing the Diagnosis and ...

42,203,268

Maandelijkse bezoeken

2,337

Alexa Rank

CA

Populair in

Up

Service status

Toegevoegd door: David Lindberg

Uitlegger

JPM Healthcare Conference Day 1: Seer, Twist, 10x ...

Jan 11, 2022 · NEW YORK – The 40th Annual JP Morgan Healthcare Conference kicked off on Monday, as conference organizers pivoted to a virtual conference instead of the usual live event at the Westin St. Francis Hotel in San Francisco due to the resurgent coronavirus pandemic. Nonetheless, the conference got off to its normal busy start with several diagnostics and …
Url: https://www.genomeweb.com/business-news/jpm-healthcare-conference-day-1-seer-twist-10x-guardant-natera-bruker-adaptive-qiagen
JPM Healthcare Conference Day 1: Seer, Twist, 10x ...

UNKNOWN

Maandelijkse bezoeken

0

Alexa Rank

UNKNOWN

Populair in

Up

Service status

Toegevoegd door: Natera

Uitlegger

Advances in testing: A personalized, ctDNA assay for MRD detection and surveillance

Advances in testing: A personalized, ctDNA assay for MRD detection and surveillance

Toegevoegd door: Natera

Uitlegger

Introducing Signatera, a personalized, tumor-informed test

Introducing Signatera, a personalized, tumor-informed test

Toegevoegd door: Natera

Uitlegger

Introducing Signatera, a personalized, tumor-informed test

Introducing Signatera, a personalized, tumor-informed test

Toegevoegd door: Natera

Uitlegger

Is the cancer coming back? Using Signatera to detect molecular residual disease (MRD)

Is the cancer coming back? Using Signatera to detect molecular residual disease (MRD)

Toegevoegd door: Natera

Uitlegger

Peace of mind powered by Signatera

Peace of mind powered by Signatera

Toegevoegd door: Natera

Uitlegger

Signatera for immunotherapy response monitoring

Signatera for immunotherapy response monitoring

Toegevoegd door: Natera

Uitlegger

The Signatera Approach

The Signatera Approach

Toegevoegd door: Total Health Conferencing | Oncology

Uitlegger

Axel Grothey, MD | What is Signatera?

Axel Grothey, MD | What is Signatera?

Toegevoegd door: Natera

Uitlegger

About Signatera and ctDNA

About Signatera and ctDNA

Toegevoegd door: Natera

Uitlegger

Steven's Story: Long-term stable disease on immunotherapy

Steven's Story: Long-term stable disease on immunotherapy
Soortgelijke vraagt
Onlangs bezocht